uPM3, a new molecular urine test for the detection of prostate cancer.
OBJECTIVE
To evaluate, in a multicenter study, the diagnostic performance of a new molecular test uPM3 for detecting prostate cancer cells in urine because of the need for better methods to identify patients at risk of prostate cancer.


METHODS
The uPM3 test is a nucleic acid amplification assay detecting simultaneously in the urine the relative expression of prostate-specific antigen (PSA) mRNA as a marker of prostate cells and PCA3RNA, which is selectively expressed in most types of prostate cancer. The test is performed using the isothermic nucleic acid-based amplification method, and the two targets are simultaneously detected in real-time fluorescence using specific beacons as probes in a thermostated spectrofluorometer. The test was performed on the first voided urine obtained after careful digital rectal examination of the prostate in men undergoing transrectal ultrasound-guided prostate biopsy.


RESULTS
Of 517 patients undergoing biopsy at five centers, 443 (86%) had an assessable sample. Of those, 21%, 55%, and 24% had a total PSA level of less than 4 ng/mL, between 4 and 10 ng/mL, and greater than 10 ng/mL. The corresponding percentage of biopsies positive for cancer in these three groups was 20%, 35%, and 44%. The overall uPM3 sensitivity and specificity was 66% and 89%, respectively. In men with a PSA level less than 4 ng/mL, the sensitivity was 74% and specificity 91%. In those with a PSA level of 4 to 10 ng/mL, the sensitivity was 58% and specificity 91%. In those with a PSA level greater than 10 ng/mL, the sensitivity and specificity was 79% and 80%, respectively. The positive predictive value of uPM3 was 75% compared with 38% for total PSA, and the negative predictive value was 84% compared with 89% and 80% for a PSA cutoff of 2.5 and 4.0 ng/mL, respectively. The overall accuracy was 81% compared with 43% and 47% for total PSA at a cutoff of 2.5 and 4.0 ng/mL, respectively.


CONCLUSIONS
These results suggest that the uPM3 molecular urine test may be an important adjunct to current methods for the detection of early prostate cancer.
Fradet
Yves
Y
Université Laval, Québec, Québec, Canada.
Saad
Fred
F
Aprikian
Armen
A
Dessureault
Jean
J
Elhilali
Mostafa
M
Trudel
Claude
C
Mâsse
Benoît
B
Piché
Lyson
L
Chypre
Camille
C
D000230:Adenocarcinoma / Q000175:diagnosis / Q000652:urine*; D000951:Antigens, Neoplasm / Q000235:genetics*; D019540:Area Under Curve; D014408:Biomarkers, Tumor / Q000652:urine*; D001707:Biopsy, Needle; D015331:Cohort Studies; D003199:Computer Systems; D006801:Humans; D008297:Male; D009363:Neoplasm Proteins / Q000235:genetics*; D021141:Nucleic Acid Amplification Techniques; D010173:Palpation; D011237:Predictive Value of Tests; D011379:Prognosis; D011467:Prostate / Q000000981:diagnostic imaging / Q000473:pathology; D017430:Prostate-Specific Antigen / Q000235:genetics*; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000652:urine*; D012333:RNA, Messenger / Q000652:urine*; D012334:RNA, Neoplasm / Q000652:urine*; D012372:ROC Curve; D012007:Rectum; D018084:Ultrasonography, Interventional
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins; D012333:RNA, Messenger; D012334:RNA, Neoplasm; C479341:prostate cancer antigen 3, human; D017430:Prostate-Specific Antigen